Generic-Drug Firms Gain as Mylan-Pfizer Deal Sparks Optimism

(Bloomberg) -- Mylan NV’s plans to combine with Pfizer Inc.’s off-patent unit was viewed by analysts as a much-needed jolt for the generic-drug industry as it contends with issues ranging from the ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.